Novel proteasome inhibitors to overcome bortezomib resistance. - Wikidata - wikimedia - TriplyDB

Novel proteasome inhibitors to overcome bortezomib resistance.

Novel proteasome inhibitors to overcome bortezomib resistance.

http://www.wikidata.org/entity/Q37878771

about

New Insights into the Function of the Immunoproteasome in Immune and Nonimmune Cells Deep sea as a source of novel-anticancer drugs: update on discovery and preclinical/clinical evaluation in a systems medicine perspective DangER: protein ovERload. Targeting protein degradation to treat myeloma When ubiquitin meets NF-κB: a trove for anti-cancer drug development Advances in the understanding of mechanisms and therapeutic use of bortezomib Targeting the ubiquitin pathway for cancer treatment Homopiperazine derivatives as a novel class of proteasome inhibitors with a unique mode of proteasome binding UBXD Proteins: A Family of Proteins with Diverse Functions in Cancer Trial Watch: Proteasomal inhibitors for anticancer therapy Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis 8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications Proteasome dysfunction in Drosophila signals to an Nrf2-dependent regulatory circuit aiming to restore proteostasis and prevent premature aging.An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma The proteomic response in glioblastoma in young patients Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation.Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis.Functional chromatography reveals three natural products that target the same protein with distinct mechanisms of action.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Development of inhibitors in the ubiquitination cascade.Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors.Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: a systematic review and meta-analysis.Inhibition of human and yeast 20S proteasome by analogues of trypsin inhibitor SFTI-1 Dynein function and protein clearance changes in tumor cells induced by a Kunitz-type molecule, Amblyomin-X The human otubain2-ubiquitin structure provides insights into the cleavage specificity of poly-ubiquitin-linkages.Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases.Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment Ubiquitination and proteolysis in acute lung injury Interplay between Structure and Charge as a Key to Allosteric Modulation of Human 20S Proteasome by the Basic Fragment of HIV-1 Tat Protein Proteasome inhibitors in mantle cell lymphoma Thiostrepton interacts covalently with Rpt subunits of the 19S proteasome and proteasome substrates.A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids.FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.Proteasome allostery as a population shift between interchanging conformers The role of allostery in the ubiquitin-proteasome system Amblyomin-X induces ER stress, mitochondrial dysfunction, and caspase activation in human melanoma and pancreatic tumor cell.The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells.From bortezomib to other inhibitors of the proteasome and beyond.Bortezomib for the treatment of non-Hodgkin's lymphoma

P2860

Q26774372-8C6976AB-BF7D-483D-96EF-63DDECD60247 Q26776294-97B5EFFE-E581-4A7B-BBFA-56DFDC092A9A Q26825417-8A7D121E-F124-4729-9E8B-1AAC13B8DE71 Q26827754-7651ED78-A04A-4E9C-BC24-D6075517414C Q26849940-89F3A996-58F6-47E1-9CFD-D90F0B2F0DA9 Q26866185-95B008AC-1252-4BD8-8A06-8D33AA2D7395 Q27677425-7FBBA7C2-3CA1-4BDC-85DA-80EE26C0969C Q28069036-83E5AA90-7A6D-48B8-A0DA-74E56FD127A9 Q28082910-34F124A5-369C-4B95-A62C-69B222ED169D Q28269674-9FE9F05E-36BD-4D4E-A3C5-2DDF762A3184 Q28389539-37306A3B-7488-4CAC-A00A-171EAB95EBF5 Q28390091-A24628DE-0F7F-4478-8076-5CB12DC95809 Q34008600-2C1A0930-FE91-4CFD-B11E-A8767E12467A Q34030167-781F4B93-DF9C-4B4E-903F-5E9767DD230C Q34043797-B874E038-211C-4C5B-BAA0-51FAB9401F6A Q34079481-0DA82AFA-9061-4D56-A3F7-F245AB8BED5F Q34195083-6F392EC9-F905-4DFD-AAE3-5D403B962303 Q34289909-FD50F0E6-9AEB-4D84-BD49-369E8D62137D Q34295600-22AC52A8-7A50-4A31-910E-CB1F7134B9BC Q34788381-EF6CF146-E1C8-4783-8D25-E19FD180131B Q35044801-EAD6BC4D-FFE0-4CDC-A708-B78F81EE4F4C Q35052044-F11D8091-628B-417C-8673-642ED9F31728 Q35104606-11C6A03C-8771-4636-80F9-5692A083C407 Q35107386-E3353DD2-493A-4966-A98F-5319AD6A43E1 Q35494324-8B81F3E3-845F-4E51-A92E-75B371A15776 Q35543082-C6F271B2-C75B-4873-BDF1-01DBA91BD161 Q35559055-18DCB0AD-C8DC-4B80-BC16-52A8322ACC07 Q35681957-008F0B78-0010-418C-B281-AC955642D02F Q35811448-6B8E2B09-64E4-414F-8430-0457A3C0753E Q35843506-B496113A-632D-41F4-8F36-19C54FD5463D Q36028745-73940D07-9F22-4539-A1B3-652031637C31 Q36057485-351E819C-7D61-4E1A-8344-5E5EE1E26F44 Q36290627-0AF2DC4F-9AEF-469F-8E84-C25B0BD7225B Q36293871-B9126FA5-E216-4AEE-9ECD-ADF909BF5CD5 Q36483667-FF0202A3-93B3-43AE-A970-4CF194621B27 Q36721779-4886696B-E1BF-42E4-8DCE-1564B5E5AE06 Q36762799-801F6A96-7490-4425-8E73-4135DE5213FE Q36815262-A139FF04-14F6-4953-AB18-37C0503565CE Q36852277-CAB486A7-9648-4E36-AFEC-C53EAF3213C9 Q36868056-A77B6366-1EFA-491D-B6E4-B54FC7853082

P2860

Novel proteasome inhibitors to overcome bortezomib resistance.

http://www.wikidata.org/entity/Q37878771

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 23 May 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Novel proteasome inhibitors to overcome bortezomib resistance.

@en

Novel proteasome inhibitors to overcome bortezomib resistance.

@nl

type

label

Novel proteasome inhibitors to overcome bortezomib resistance.

@en

Novel proteasome inhibitors to overcome bortezomib resistance.

@nl

prefLabel

Novel proteasome inhibitors to overcome bortezomib resistance.

@en

Novel proteasome inhibitors to overcome bortezomib resistance.

@nl

P1433

Q37878771-3479A009-8922-4629-AE8E-F46CE7D85AE3

P1476

Q37878771-2BCE7E36-6C86-4A06-B1F2-5E44A1C7994F

P2093

Q37878771-0FF5005C-34D9-4C18-8E35-60F72E18EC2D

Q37878771-5D23ACF8-2BEA-430B-9D8B-B823C29827CA

P2860

Q37878771-0614EF7F-D648-4758-A126-0B2E9227F091

Q37878771-086A0C3C-3B58-4E58-8995-E0289692B975

Q37878771-09991333-2FF8-4835-AF32-6831909A4F41

Q37878771-0B5C4A25-A35F-40A2-BE44-ED1CF4C27AD7

Q37878771-0D14806D-F758-4934-94D5-022CBD8BF65C

Q37878771-127B0BC7-8210-475E-AED5-A3D6B12247D1

Q37878771-190A8B9B-E1A1-43CB-808A-93497825DFAF

Q37878771-1F84FB7D-685C-4213-B4F8-0E63830EA115

Q37878771-1FEB1228-3265-4DA0-AF9B-379DE07A6F82

Q37878771-22B14DF9-9699-48D6-85EC-C58DCD3CE5CC

P304

Q37878771-399E17B9-4C03-4678-A811-607756F428D6

P31

Q37878771-21D5EFA7-DCC8-470F-8B74-E4C5F61E9321

P356

Q37878771-72F1429A-D473-44F7-BFC5-22864217DBFB

P407

Q37878771-DAFA09F8-7E7A-4BAA-9961-2333B73A48A6

P433

Q37878771-86235F50-05A1-43EE-9FBB-4F0AF9079E3D

P478

Q37878771-384999D0-EDBC-4883-B033-9729B00A7506

P50

Q37878771-05796076-C71E-4D72-BCB4-31AAAD8BD571

Q37878771-3D22E341-D67E-4137-93D1-71246B4A31B7

P577

Q37878771-6B26928D-5D92-4203-BB04-2C950EF5D0EE

P5875

Q37878771-74DCE78D-5D3B-4B4F-99AB-81BEED50D200

P698

Q37878771-DEEEEA90-8814-431E-AF3C-4FA9419CDDC4

P356

P1433

Journal of the National Cancer Institute

P1476

Novel proteasome inhibitors to overcome bortezomib resistance.

@en

P2093

Amy M Ruschak

http://www.w3.org/2001/XMLSchema#string

Malik Slassi

http://www.w3.org/2001/XMLSchema#string

P2860

Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.

Structure and functions of the 20S and 26S proteasomes

Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1

Structure of the gene for porcine peptide antibiotic PR-39, a cathelin gene family member: comparative mapping of the locus for the human peptide antibiotic FALL-39

Histone H2A monoubiquitination represses transcription by inhibiting RNA polymerase II transcriptional elongation

A gated channel into the proteasome core particle

The structure of the mammalian 20S proteasome at 2.75 A resolution

Insights into the ubiquitin transfer cascade from the structure of the activating enzyme for NEDD8

The structure of the APPBP1-UBA3-NEDD8-ATP complex reveals the basis for selective ubiquitin-like protein activation by an E1

Interactions of PAN's C-termini with archaeal 20S proteasome and implications for the eukaryotic proteasome–ATPase interactions

P304

1007-1017

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJR160

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51159901

http://www.w3.org/2001/XMLSchema#string

P698

21606441

http://www.w3.org/2001/XMLSchema#string